Kymera Therapeutics Stock Market Value
| KYMR Stock | USD 40.61 0.32 0.79% |
| Symbol | Kymera |
Kymera Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kymera Therapeutics. If investors know Kymera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kymera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.36) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of Kymera Therapeutics is measured differently than its book value, which is the value of Kymera that is recorded on the company's balance sheet. Investors also form their own opinion of Kymera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Kymera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kymera Therapeutics' market value can be influenced by many factors that don't directly affect Kymera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kymera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kymera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kymera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Kymera Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kymera Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kymera Therapeutics.
| 12/19/2024 |
| 01/18/2025 |
If you would invest 0.00 in Kymera Therapeutics on December 19, 2024 and sell it all today you would earn a total of 0.00 from holding Kymera Therapeutics or generate 0.0% return on investment in Kymera Therapeutics over 30 days. Kymera Therapeutics is related to or competes with Foghorn Therapeutics, Shattuck Labs, Monte Rosa, Nurix Therapeutics, Revolution Medicines, C4 Therapeutics, and Agios Pharm. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule thera... More
Kymera Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kymera Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kymera Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 18.1 | |||
| Value At Risk | (6.47) | |||
| Potential Upside | 5.88 |
Kymera Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kymera Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kymera Therapeutics' standard deviation. In reality, there are many statistical measures that can use Kymera Therapeutics historical prices to predict the future Kymera Therapeutics' volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.12) |
Kymera Therapeutics Backtested Returns
Kymera Therapeutics has Sharpe Ratio of -0.0441, which conveys that the firm had a -0.0441% return per unit of risk over the last 3 months. Kymera Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kymera Therapeutics' Mean Deviation of 2.85, standard deviation of 3.73, and Risk Adjusted Performance of (0.02) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.14, which conveys a somewhat significant risk relative to the market. Kymera Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Kymera Therapeutics is expected to follow. At this point, Kymera Therapeutics has a negative expected return of -0.16%. Please make sure to verify Kymera Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Kymera Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.28 |
Weak reverse predictability
Kymera Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Kymera Therapeutics time series from 19th of December 2024 to 3rd of January 2025 and 3rd of January 2025 to 18th of January 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kymera Therapeutics price movement. The serial correlation of -0.28 indicates that nearly 28.0% of current Kymera Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.28 | |
| Spearman Rank Test | -0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 2.7 |
Kymera Therapeutics lagged returns against current returns
Autocorrelation, which is Kymera Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Kymera Therapeutics' stock expected returns. We can calculate the autocorrelation of Kymera Therapeutics returns to help us make a trade decision. For example, suppose you find that Kymera Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Kymera Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Kymera Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Kymera Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Kymera Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Kymera Therapeutics Lagged Returns
When evaluating Kymera Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Kymera Therapeutics stock have on its future price. Kymera Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Kymera Therapeutics autocorrelation shows the relationship between Kymera Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Kymera Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Kymera Stock
Moving against Kymera Stock
| 0.73 | DRTS | Alpha Tau Medical | PairCorr |
| 0.73 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.58 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.52 | VCEL | Vericel Corp Ord | PairCorr |
| 0.52 | SABSW | SAB Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.